Efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer: A systematic review of clinical trials

Ali, Muhammad Ashar; Aiman, Wajeeha; Shah, Syed Sajid Hussain; Hussain, Muddassar; Kashyap, Richi

doi:10.1016/j.critrevonc.2020.103197

Cited by 11 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently study conducted in Pakistan presented same results that injection pembrolizumab was an effective and useful monotherapy among patients with PD-L1positive mTNBC with less adverse outcomes and higher rate of efficacy. [18] Other studies using immune checkpoint inhibitors for mTNBC treatment have shown similar results. mTNBC was treated with pembrolizumab in the KEYNOTE-012 research, which found an ORR of 18.5%, a median latency to response of 4.1 months, and an unreachable median response duration (between 3.4 and 10.9 months) in the 32 participants.…”

Section: Discussionmentioning

confidence: 54%

Comparative Analysis of Pembrolizumab and Chemotherpay with Radiology Among Patients of Untreated Pd-L1 Positive Metastatic Triple Negative Breast Cancer

Mubarak¹,

Sukhera²,

Shujat³

2021

PJMHS

View full text Add to dashboard Cite

Objective: The aim of this study is to compare the outcomes of chemotherapy with radiology and use of pembrolizumab among the patients had metastatic triple negative breast cancer and did not receive any treatment yet. Study Design: Comparative/Observational study. Place and Duration: Breast Clinic Ganga Ram Hospital Mazang Road, Lahore. April 2021-Sep 2021 Methods: Total 70 patients of aged 25-75 years were presented in this study. Patients had metastatic triple negative breast cancer and did not receive any treatment yet were included. Demographically detailed of enrolled cases age, body mass index, co-morbidities and literacy were calculated after taking informed written consent. Patients were equally divided into two groups, I and II. Group I had 35 patients and received pembrolizumab 200 mg every 2-weeks for six months while in group II 35 patients received chemotherapy (75mg Adriamycin) every 21-days for six months. Regular follow up among patients were conducted. Post-treatment outcomes among both groups were assessed and compared in terms of efficacy, control of disease, mortality and recurrence rate. SPSS 24.0 version was used to analyze complete data. Results: Mean age of the patients in group I was 58.01±4.34 years with mean BMI 28.21±6.22 kg/m2 and in group II mean age was 57.88±6.88 years with mean BMI 27.94±9.42 kg/m2. Frequency of literacy in group I was 18 (51.4%) and in group II 20 (57.1%) patients were literate. Hypertension was the most common comorbidity found in 13 (37.1%) in group I and 14 (40%) in group II followed by arthritis and diabetes mellitus. Post-treatment effectiveness in group I was 15 (42.9%) higher as compared to group II 10 (28.6%), partial recovery found in 11 (31.4%) and 8 (22.9%) among both groups, stability in disease was found higher among patients of group II 12 (34.3%) as compared to group I 7 (20%). Mortality in group I was 3 (8.6%) and in group II 5 (14.3%). Recurrence rate in pembrolizumab group was 2 (5.7%) lower as compared to chemotherapy group 4 (11.4%). Conclusion: In this research we concluded that the use of pembrolizumab injection for the treatment of breast cancer was effective and useful in terms of low mortality rate with recurrence rate and higher number of recovery, but rate of stability among disease was higher in chemotherapy group. Both treatments were effective for reduction in the prevalence of disease. Keywords: Breast Cancer, Chemotherapy, Pembrolizumab, Mortality, Recurrence

show abstract

Section: Discussionmentioning

confidence: 54%

Comparative Analysis of Pembrolizumab and Chemotherpay with Radiology Among Patients of Untreated Pd-L1 Positive Metastatic Triple Negative Breast Cancer

Mubarak¹,

Sukhera²,

Shujat³

2021

PJMHS

View full text Add to dashboard Cite

show abstract

“…Immune checkpoint inhibitors, including atezolizumab, which targets programmed cell death ligand 1 (PD-L1), and pembrolizumab, which targets programmed cell death receptor 1 (PD-1), are approved by the Food and Drug Administration (FDA) in locally advanced, non-resectable, and metastatic patients ( www.fda.gov ). 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 Atezolizumab is given with nab-paclitaxel, 11 and pembrolizumab is given with a broader range of chemotherapeutics. 10 Pembrolizumab has also been approved with chemotherapy (various) in high-risk primary TNBC in the neoadjuvant setting.…”

Section: Introductionmentioning

confidence: 99%

Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach

Petrosyan¹,

Dobrolecki²,

Thistlethwaite³

et al. 2023

iScience

View full text Add to dashboard Cite

“…Checkpoint inhibitors, including PD-1, programmed death-ligand 1 (PD-L1), and CTLA-4 inhibitors, have shown efficacy in urothelial and other solid tumors [62][63][64][65]. However, the microenvironment of prostate cancer is more immunosuppressive as compared to other tumors [66,67].…”

Section: Discussionmentioning

confidence: 99%

Current Status of Monoclonal Antibodies-Based Therapies in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials

Tarrar¹,

Anwar²,

Ali³

et al. 2022

Cureus

Self Cite

View full text Add to dashboard Cite

BackgroundMultiple patients with prostate cancer become resistant to castration therapies, which is termed castrationresistant prostate cancer (CRPC). PurposeThe purpose of this review is to assess the status of efficacy (≥50% decline in prostate-specific antigen (PSA), progression-free survival (PFS), and overall survival (OS)) and safety (grade 3-4 adverse effects) of monoclonal antibodies in CRPC. Data sourceWe searched databases including PubMed, Embase, Cochrane, Web of Science, and ClinicalTrials.gov. ResultsHazard ratios of PFS and OS were 0.77 (95% CI = 0.69-0.87, I 2 = 53%) and 0.98 (95% CI = 0.86-1.11, I 2 = 40%), respectively, in the favor of monoclonal antibodies as compared to placebo. Risk ratio (RR) of >50% decline in PSA was 1.99 (95% CI = 0.97-4.08, I 2 = 53%) in favor of monoclonal antibodies. Pooled incidence of >50% decline in PSA levels was 15% (95% CI = 0.1-0.23, I 2 = 83%), 29% (95% CI = 0.14-0.51, I 2 = 93%), 63% (95% CI = 0.49-0.76, I 2 = 77%), and 88% (95% CI = 0.81-0.93, I 2 = 0%) in single, two, three, and four-drug regimens, respectively. ConclusionMonoclonal antibodies are well tolerated and showed better PFS as compared to placebo. However, OS was only improved with ipilimumab. Denosumab delayed skeletal-related adverse events as compared to zoledronic acid. More multicenter double-blind clinical trials may be needed to confirm these results.

show abstract

Efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer: A systematic review of clinical trials

Cited by 11 publications

References 39 publications

Comparative Analysis of Pembrolizumab and Chemotherpay with Radiology Among Patients of Untreated Pd-L1 Positive Metastatic Triple Negative Breast Cancer

Comparative Analysis of Pembrolizumab and Chemotherpay with Radiology Among Patients of Untreated Pd-L1 Positive Metastatic Triple Negative Breast Cancer

Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach

Current Status of Monoclonal Antibodies-Based Therapies in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials

Contact Info

Product

Resources

About